Interplay between innate immunity and the viral oncoproteins Tax and HBZ in the pathogenesis and therapeutic response of HTLV-1 associated adult T cell leukemia

dc.contributor.authorEl-Hajj, Hiba Ahmad
dc.contributor.authorBazarbachi, Ali Abdul Hamid
dc.contributor.departmentExperimental Pathology, Microbiology, and Immunology
dc.contributor.departmentInternal Medicine
dc.contributor.departmentAnatomy, Cell Biology, and Physiological Sciences
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:39:10Z
dc.date.available2025-01-24T11:39:10Z
dc.date.issued2022
dc.description.abstractThe Human T-cell Leukemia virus type 1 (HTLV-1) causes an array of pathologies, the most aggressive of which is adult T-cell leukemia (ATL), a fatal blood malignancy with dismal prognosis. The progression of these diseases is partly ascribed to the failure of the immune system in controlling the spread of virally infected cells. HTLV-1 infected subjects, whether asymptomatic carriers or symptomatic patients are prone to opportunistic infections. An increasing body of literature emphasizes the interplay between HTLV-1, its associated pathologies, and the pivotal role of the host innate and adoptive immune system, in shaping the progression of HTLV-1 associated diseases and their response to therapy. In this review, we will describe the modalities adopted by the malignant ATL cells to subvert the host innate immune response with emphasis on the role of the two viral oncoproteins Tax and HBZ in this process. We will also provide a comprehensive overview on the function of innate immunity in the therapeutic response to chemotherapy, anti-viral or targeted therapies in the pre-clinical and clinical settings. Copyright © 2022 El Hajj and Bazarbachi.
dc.identifier.doihttps://doi.org/10.3389/fimmu.2022.957535
dc.identifier.eid2-s2.0-85135547487
dc.identifier.pmid35935975
dc.identifier.urihttp://hdl.handle.net/10938/29198
dc.language.isoen
dc.publisherFrontiers Media S.A.
dc.relation.ispartofFrontiers in Immunology
dc.sourceScopus
dc.subjectAtl/atll
dc.subjectHbz
dc.subjectHtlv-1/htlv-1
dc.subjectInnate immunity
dc.subjectInterleukin-10 (il-10)
dc.subjectTargeted therapy/therapies
dc.subjectTax
dc.subjectAdult
dc.subjectBasic-leucine zipper transcription factors
dc.subjectHuman t-lymphotropic virus 1
dc.subjectHumans
dc.subjectImmunity, innate
dc.subjectLeukemia-lymphoma, adult t-cell
dc.subjectOncogene proteins, viral
dc.subjectRetroviridae proteins
dc.subjectBasic leucine zipper transcription factor
dc.subjectGamma interferon
dc.subjectInterleukin 10
dc.subjectInterleukin 8
dc.subjectLeucine zipper protein
dc.subjectTax protein
dc.subjectViral oncoprotein
dc.subjectHbz protein, human t-cell leukemia virus type i
dc.subjectOncoprotein
dc.subjectViral protein
dc.subjectAdult t cell leukemia
dc.subjectCell migration
dc.subjectCell proliferation
dc.subjectChemotherapy
dc.subjectHuman
dc.subjectImmune response
dc.subjectImmune system
dc.subjectImmunogenicity
dc.subjectInflammation
dc.subjectLeukemogenesis
dc.subjectPathogenesis
dc.subjectPreclinical study
dc.subjectReview
dc.subjectTreatment response
dc.subjectMetabolism
dc.subjectT cell leukemia
dc.titleInterplay between innate immunity and the viral oncoproteins Tax and HBZ in the pathogenesis and therapeutic response of HTLV-1 associated adult T cell leukemia
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2022-1670.pdf
Size:
1.29 MB
Format:
Adobe Portable Document Format